OBJECTIVE: The present study aims to evaluate changes in proteomic salivary profile of @entity1 with @entity3136 after @entity5 treatments. MATERIALS AND METHODS: Samples were collected from @entity1 after @entity5 therapies, and were analyzed by means of SELDI/ @entity215 . @entity1 were separated in two groups: @entity1 affected by @entity33 ( @entity33 ) and @entity1 without @entity33 (NO @entity33 ). All @entity1 were divided in function of the anticancer treatment: @entity1 who had radiotherapy ( @entity33 RADIO), had not radiotherapy ( @entity33 NO RADIO), had chemotherapy ( @entity33 CHEMO) and those who had not chemotherapy ( @entity33 NO CHEMO). Statistical evaluation PCA (Principal Component Analysis), was conducted with the software BIO-RAD Data Manager (   ) (Version 3.5). RESULTS: We found the increased peaks of 3443, 3487, 4135 m/z in @entity33 group, while 6237 m/z was reduced. The same peaks would the same modifications in @entity33 RADIO, while in @entity33 CHEMIO are increased 3443 and 6237 m/z but 3487, 4135 m/z are reduced. These data were confirmed by the Principal Component Analysis (PCA). CONCLUSION: Anticancer therapy influenced the level expression of many salivary biomarkers in @entity33 with a good significance. Therefore 3443, 3487, 4135 and 6237 m/z are good biomarker candidates of @entity3136 . This article is protected by copyright. All rights reserved.

Expression of salivary biomarkers in XXXX with @entity3136 : evaluation by SELDI- @entity215 /MS.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity3136 :: ('MESH:D013280', 'Disease') :: ['oral mucositis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['adjuvant cancer'] @entity215 :: ('MESH:D013771', 'Disease') :: ['TOF'] @entity33 :: ('MESH:D052016', 'Disease') :: ['MUCOSITIS', 'mucositis']
@entity1 :: (9606,Species) :: ['patients']
